Bulk Pharmaceutical API Sources for GLYBURIDE (MICRONIZED)

Bulk Pharmaceutical API Sources for GLYBURIDE (MICRONIZED)

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		G2539_SIAL
Sigma-Aldrich		G0639_SIGMA
Vitas-M Laboratory		STK362992
Molport		MolPort-000-784-850

GLYBURIDE (MICRONIZED) BULK ACTIVE PHARMACEUTICAL INGREDIENT (API) SOURCING

Last updated: February 19, 2026

This report analyzes the global supply landscape for micronized glyburide bulk API. Key findings include a competitive market dominated by manufacturers in Asia, primarily India and China, with a significant presence of contract manufacturing organizations (CMOs). Regulatory compliance, particularly U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards, is a critical factor influencing supplier selection. Lead times and supply chain robustness are also primary considerations for pharmaceutical companies.

What is the Global Supply Landscape for Micronized Glyburide API?

The global supply of micronized glyburide bulk API is characterized by a fragmented manufacturing base with a concentration of producers in Asia, specifically India and China. These regions benefit from lower production costs and established chemical synthesis capabilities. A substantial portion of global production is undertaken by Contract Manufacturing Organizations (CMOs) that cater to multiple pharmaceutical clients, offering flexibility and scalability. The market is competitive, with pricing influenced by production volume, purity standards, and regulatory certifications.

Who are the Key Manufacturers of Micronized Glyburide API?

Key manufacturers and suppliers of micronized glyburide API are predominantly located in India and China. These companies often possess U.S. FDA Establishment Inspection Reports (EIRs) and Certificates of Suitability (CEPs) from the European Directorate for the Quality of Medicines & HealthCare (EDQM), demonstrating their adherence to international quality standards.

Table 1: Selected Micronized Glyburide API Manufacturers

Company Name	Country of Origin	Primary Manufacturing Site	Regulatory Approvals (Examples)
Aarti Drugs Ltd.	India	India	US FDA, EDQM, WHO GMP
Sun Pharmaceutical Industries Ltd.	India	India	US FDA, EDQM
Dr. Reddy's Laboratories	India	India	US FDA, EDQM
Divi's Laboratories	India	India	US FDA, EDQM
Liansheng Pharmaceutical Group	China	China	US FDA (pending/approved sites)
CSPC Pharmaceutical Group	China	China	CFDA, WHO GMP
Jiangsu Pharma	China	China	CFDA

Source: Manufacturer websites, regulatory filings, industry reports [1, 2, 3]. Note: Specific product availability and manufacturing site approvals can vary and require direct confirmation.

What are the Key Regulatory Requirements for Micronized Glyburide API?

Manufacturers of micronized glyburide API must comply with stringent regulatory requirements to ensure product quality, safety, and efficacy. These include adherence to Good Manufacturing Practices (GMP) as defined by regulatory bodies such as the U.S. FDA, the European Medicines Agency (EMA), and national authorities.

• U.S. FDA: Compliance with 21 CFR Part 210 and 211. Manufacturers often undergo FDA inspections, and successful inspection outcomes are documented in Establishment Inspection Reports (EIRs).
• European Medicines Agency (EMA): Adherence to EudraLex Volume 4. Obtaining a Certificate of Suitability (CEP) from the EDQM is a common pathway for demonstrating compliance for the European market.
• ICH Guidelines: Manufacturers are expected to follow International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q7 for Active Pharmaceutical Ingredients.
• Pharmacopoeial Standards: The API must meet specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).

What are the Critical Quality Attributes (CQAs) for Micronized Glyburide API?

Micronized glyburide API requires precise control over several critical quality attributes (CQAs) to ensure its performance in finished dosage forms. Micronization is a key process step that influences bioavailability.

• Particle Size Distribution (PSD): This is paramount for micronized glyburide. A narrow and consistent PSD is essential for achieving predictable dissolution rates and therapeutic efficacy. Typical specifications are in the low-micron range, often with D90 values below 10-20 micrometers. Deviations can lead to variable absorption and therapeutic outcomes.
• Purity and Impurity Profile: The API must be free from significant levels of related substances, residual solvents, and heavy metals. Limits are defined by pharmacopoeias and ICH guidelines.
• Polymorphism: Glyburide exhibits polymorphism, and specific crystalline forms can affect solubility and stability. Manufacturers must control the polymorphic form to ensure consistent product performance.
• Assay: The concentration of glyburide must fall within defined limits, typically 98.0% to 102.0% on a dried basis, as per USP.
• Water Content: Controlled to prevent degradation and maintain stability.
• Microbial Limits: Adherence to specified limits for microbial contamination.

What are the Typical Lead Times and Supply Chain Considerations?

Lead times for bulk micronized glyburide API can range from 8 to 20 weeks, depending on the manufacturer's existing production schedules, order volume, and logistical arrangements. Supply chain robustness is a critical consideration for pharmaceutical companies to mitigate risks of stock-outs and ensure continuity of medication supply.

• Order Volume: Larger orders may require longer lead times due to manufacturing batch sizes and scheduling.
• Inventory Management: Manufacturers may maintain limited inventories of finished API, necessitating production runs upon order placement.
• Geopolitical Stability: Reliance on specific geographic regions for manufacturing can introduce risks related to trade disputes, natural disasters, or political instability.
• Logistics and Shipping: International shipping involves customs, transit times, and potential delays. Cold chain or specialized handling is generally not required for glyburide API, simplifying logistics.
• Dual Sourcing: Pharmaceutical companies often engage in dual sourcing strategies to ensure supply chain resilience and negotiate better pricing.

What are the Price Drivers for Micronized Glyburide API?

The price of micronized glyburide API is influenced by several factors, including raw material costs, manufacturing complexity, scale of production, regulatory compliance overhead, and market demand.

• Raw Material Costs: The cost of starting materials and intermediate chemicals used in glyburide synthesis directly impacts API pricing.
• Manufacturing Scale: Larger production volumes typically lead to lower per-unit costs due to economies of scale.
• Regulatory Compliance: Investment in quality systems, validation, and regulatory submissions adds to the cost of production. Manufacturers with established regulatory track records may command higher prices.
• Micronization Process: The micronization step, requiring specialized equipment and process control, adds to manufacturing costs compared to standard particle size APIs.
• Market Demand and Competition: High demand relative to supply can drive prices upward, while intense competition among suppliers generally leads to more competitive pricing.
• Purity and Specifications: APIs meeting stricter pharmacopoeial standards or with tighter impurity limits may be priced at a premium.

How to Qualify a New Micronized Glyburide API Supplier?

Qualifying a new micronized glyburide API supplier is a multi-stage process requiring thorough due diligence to ensure compliance, quality, and reliability.

1. Initial Screening:
   • Review of company profile, manufacturing experience, and financial stability.
   • Verification of existing regulatory approvals (e.g., FDA EIR, EDQM CEP).
   • Assessment of product documentation, including Drug Master Files (DMFs) or Active Substance Master Files (ASMFs).
2. Quality System Audit:
   • On-site audit of manufacturing facilities to assess adherence to GMP.
   • Review of quality control laboratories, analytical methods, and validation status.
   • Examination of change control, deviation management, and CAPA systems.
3. Technical Evaluation:
   • Review of the proposed manufacturing process, including synthesis route and critical process parameters.
   • Assessment of the micronization process and control of particle size distribution.
   • Evaluation of the impurity profiling and analytical methods.
   • Confirmation of polymorphic form control.
4. Sample Testing:
   • Procurement and testing of API samples under Good Laboratory Practices (GLP) conditions.
   • Verification of key quality attributes against agreed specifications.
5. Regulatory Assessment:
   • Review of regulatory submission history and inspection outcomes.
   • Ensuring alignment with specific market requirements for the finished drug product.
6. Supply Chain and Business Continuity:
   • Assessment of raw material sourcing and supply chain resilience.
   • Review of business continuity plans in case of disruptions.
   • Negotiation of supply agreements, including quality agreements.

Key Takeaways

• The global market for micronized glyburide API is dominated by manufacturers in India and China, offering a competitive pricing environment.
• Strict adherence to GMP and pharmacopoeial standards, evidenced by FDA and EDQM approvals, is non-negotiable for market access and supplier qualification.
• Particle size distribution is a critical quality attribute for micronized glyburide, directly impacting bioavailability and therapeutic efficacy.
• Lead times can extend up to 20 weeks, necessitating proactive inventory planning and dual sourcing strategies to ensure supply chain security.
• Supplier qualification is a rigorous process involving technical, quality, and regulatory due diligence.

Frequently Asked Questions

1. What is the typical purity specification for micronized glyburide API? Micronized glyburide API typically requires a purity of not less than 98.0% and not more than 102.0% on a dried basis, as per USP specifications.
2. Are there specific polymorphic forms of glyburide that are preferred for API manufacturing? While glyburide exhibits polymorphism, manufacturers must consistently produce and control the specified polymorphic form as detailed in the drug master file and validated by the finished product manufacturer. The specific preferred form is dictated by the performance characteristics demonstrated during drug product development.
3. What is the impact of particle size on glyburide bioavailability? Micronization of glyburide is performed to increase its surface area, which in turn enhances its dissolution rate. A finer and more consistent particle size distribution leads to improved and more predictable absorption in the gastrointestinal tract, thereby improving bioavailability.
4. Can Chinese manufacturers provide APIs that meet U.S. FDA standards? Yes, many Chinese API manufacturers have successfully undergone U.S. FDA inspections and obtained Establishment Inspection Reports (EIRs), enabling them to supply APIs for the U.S. market. However, individual facility approvals must be verified.
5. What are the key differences between micronized and non-micronized glyburide API? The primary difference lies in particle size. Micronized glyburide API has a significantly reduced particle size (in the low-micron range), leading to increased surface area and faster dissolution, which is crucial for achieving adequate oral bioavailability. Non-micronized glyburide has larger particles and a slower dissolution rate, potentially leading to lower and more variable absorption.

Citations

[1] Aarti Drugs Ltd. (n.d.). Product List. Retrieved from [Manufacturer Website] [2] Sun Pharmaceutical Industries Ltd. (n.d.). API Products. Retrieved from [Manufacturer Website] [3] Divi's Laboratories. (n.d.). API Portfolio. Retrieved from [Manufacturer Website]